Un nuevo enfoque terapéutico para la disfunción eréctil: las ondas de choque de baja intensidad

Herney Andrés García-Perdomo; Ginna Marcela Ocampo-Flórez

doi:10.17533/udea.iatreia.v28n3a06

Autores/as

Herney Andrés García-Perdomo Universidad del Valle
Ginna Marcela Ocampo-Flórez Universidad Libre

DOI:

https://doi.org/10.17533/udea.iatreia.v28n3a06

Palabras clave:

disfunción eréctil, endotelio vascular, erección peneana, inhibidores de fosfodiesterasa 5, ondas, satisfacción del paciente

Resumen

La disfunción eréctil es la incapacidad de lograr o mantener una erección del pene para la penetración vaginal y el desempeño sexual satisfactorio; se la considera el segundo problema más frecuente de disfunción sexual en hombres, después de la eyaculación precoz, con una prevalencia aproximada del 30%. La mayoría de los casos de disfunción eréctil tienen origen orgánico, principalmente por enfermedades vasculares, pero también está asociada a factores psicológicos, neurológicos u hormonales, o a alteraciones estructurales. La terapia farmacológica con inhibidores de la 5-fosfodiesterasa ha tenido eficacia clínica, pero hay pacientes que no responden a ella. Por tal razón se recurrió a las ondas de choque de baja intensidad que mejoran la vascularización y el flujo sanguíneo del pene con lo que se logran erecciones que permiten mejorar la calidad de la vida sexual. En esta revisión se incluyen diferentes estudios que demuestran la efectividad de este tratamiento.

|Resumen

= 592 veces | PDF

= 284 veces|

Descargas

Los datos de descargas todavía no están disponibles.

Biografía del autor/a

Herney Andrés García-Perdomo, Universidad del Valle

MD, MSc, EdDc, PhDc. Profesor, Universidad del Valle, Cali, Colombia.

Ginna Marcela Ocampo-Flórez, Universidad Libre

Medico interno. Facultad de Ciencias de la Salud. Universidad Libre Cali.

Citas

(1.) González E, Villeda CI, Sotomayor M, Ibarra R, Cálao MB, Quijada H, et al. Prevalencia de disfunción eréctil en una muestra de población joven en México. Rev Mex Urol. 2012 Sept-Oct;72(5):245-9.

(2.) Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994 Jan;151(1):54-61.

(3.) Shamloul R, Ghanem H. Erectile dysfunction. Lancet. 2013 Jan;381(9861):153-65.

(4.) Camacho ME, Reyes-Ortiz CA. Sexual dysfunction in the elderly: age or disease? Int J Impot Res. 2005 Dec;17 Suppl 1:S52-6.

(5.) Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997 Jun;49(6):822-30.

(6.) Rajfer J. Diagnostic index and dysfunction treatment. Rev Urol. 2000 Fall;2(4):227-8.

(7.) Abu-Ghanem Y, Kitrey ND, Gruenwald I, Appel B, Vardi Y. Penile low-intensity shock wave therapy: a promising novel modality for erectile dysfunction. Korean J Urol. 2014 May;55(5):295-9.

(8.) NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA. 1993 Jul;270(1):83-90.

(9.) Smith JF, Breyer BN, Shindel AW. Predictors of sexual bother in a population of male North American medical students. J Sex Med. 2011 Dec;8(12):3363-9.

(10.) Celada A, Tárraga PJ, Rodríguez JA, Solera J, López MA, Arjona E. Disfunción eréctil asociada a factores de riesgo cardiovascular. Clin Invest Arterioscl. 2011 Nov-Dic;23(6):253-61.

(11.) Gades NM, Nehra A, Jacobson DJ, McGree ME, Gir-man CJ, Rhodes T, et al. Association between smoking and erectile dysfunction: a population-based study. Am J Epidemiol. 2005 Feb 15;161(4):346-51.

(12.) Guirao Sánchez L, García-Giralda Ruiz L, Sandoval Martínez C, Mocciaro Loveccio A. [Erectile dysfunction in primary care as possible marker of health status: associated factors and response to sildenafil]. Aten Primaria. 2002 Sep;30(5):290-6. Spanish.

(13.) Cunningham GR, Rosen RC, Snyder PJ, O’Leary MP, Martin KA. Overview of male sexual dysfunction. Vol. 19.2. [Internet]. Walthman (MA): UpToDate; 2011. Available from: http://www.uptodate.com/contents/overview-of-male-sexual-dysfunction

(14.) Rynja S, Bosch R, Kok E, Wouters G, de Kort L. IIEF-15: unsuitable for assessing erectile function of young men? J Sex Med. 2010 Aug;7(8):2825-30.

(15.) Pushkar' DIu, Kamalov AA, Al'-Shukri SKh, Erkovich AA, Kogan MI, Pavlov VN, et al. [Analysis of the results of epidemiological study on prevalence of erectile dysfunction in the Russian Federation]. Urologia. 2012 Sep-Oct;(6):5-9. Russian.

(16.) Martin-Morales A, Sanchez-Cruz JJ, Saenz de Tejada I, Rodriguez-Vela L, Jimenez-Cruz JF, Burgos-Rodriguez R. Prevalence and independent risk factors for erecti-le dysfunction in Spain: results of the Epidemiologia de la Disfuncion Erectil Masculina Study. J Urol. 2001 Aug;166(2):569-74.

(17.) Bosser G, Chodek-Hingray A, Kazmierczak C, Juillière Y. [Sexual activity and cardiovascular risks]. Presse Med. 2014 Oct;43(10 Pt 1):1097-105. French.

(18.) Patel DV, Halls J, Patel U. Investigation of erectile dysfunction. Br J Radiol. 2012 Nov;85 Spec No 1:S69-78.

(19.) Prieto Castro R, Campos Hernández P, Robles Casilda R, Ruíz García J, Requena Tapia MJ. Epidemiología de la disfunción eréctil: Factores de riesgo. Arch Españoles Urol. 2010 Oct;63(8):637-9.

(20.) Gutiérrez PR, Cabello F. Inhibidores de la fosfodiesterasa 5: calidad de la erección y repercusión emocional en los varones con disfunción eréctil y sus parejas. Rev Int Androl. 2010 Oct-Dic;8(4):155-64.

(21.) Saenz de Tejada I, Moroukian P, Tessier J, Kim JJ, Goldstein I, Frohrib D. Trabecular smooth muscle modulates the capacitor function of the penis. Studies on a rabbit model. Am J Physiol. 1991 May;260(5 Pt 2):H1590-5.

(22.) Ali W, Besarani D, Kirby R. Review: Modern treatment of erectile dysfunction. Br J Diabetes Vasc Dis. 2002 Jul-Ago;2(4):255-61.

(23.) Cellek S, Moncada S. Nitrergic control of peripheral sympathetic responses in the human corpus cavernosum: a comparison with other species. Proc Natl Acad Sci U S A. 1997 Jul;94(15):8226-31.

(24.) McVary KT. Clinical practice. Erectile dysfunction. N Engl J Med. 2007 Dec;357(24):2472-81.

(25.) Qiu X, Lin G, Xin Z, Ferretti L, Zhang H, Lue TF, et al. Effects of low-energy shockwave therapy on the erectile function and tissue of a diabetic rat model. J Sex Med. 2013 Mar;10(3):738-46.

(26.) Dorsey P, Keel C, Klavens M, Hellstrom WJG. Phospho-diesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction. Expert Opin Pharmacother. 2010 May;11(7):1109-22.

(27.) Aversa A, Bruzziches R, Francomano D, Natali M, Lenzi A. Testosterone and phosphodiesterase type-5 inhibitors: new strategy for preventing endothelial damage in internal and sexual medicine? Ther Adv Urol. 2009 Oct;1(4):179-97.

(28.) Tsertsvadze A, Fink HA, Yazdi F, MacDonald R, Bella AJ, Ansari MT, et al. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. Ann Intern Med. 2009 Nov;151(9):650-61.

(29.) Wespes E, Amar E, Eardley I, Giuliano F, Hatzichristou D, Hatzimouratidis K, et all. Farmacoterapia tópica. En: Guía clínica sobre la disfunción sexual masculina: disfunción eréctil y eyaculación precoz. Arnhem: European Association of Urology; 2010. p. 868-9.

(30.) Cabello R, Moncada I. Prótesis de pene: revisión histórica, descripción de la técnica y complicaciones. Rev Int Androl. 2007 Jul;5(3):248-57.

(31.) Chaussy C, Brendel W, Schmiedt E. Extracorporeally induced destruction of kidney stones by shock waves. Lancet. 1980 Dec;2(8207):1265-8.

(32.) Rassweiler JJ, Knoll T, Köhrmann K-U, McAteer JA, Lingeman JE, Cleveland RO, et al. Shock wave technology and application: an update. Eur Urol. 2011 May;59(5):784-96.

(33.) Qureshi AA, Ross KM, Ogawa R, Orgill DP. Shock wave therapy in wound healing. Plast Reconstr Surg . 2011 Dec;128(6):721e-7e.

(34.) Aicher A, Heeschen C, Sasaki K, Urbich C, Zeiher AM, Dimmeler S. Low-energy shock wave for enhancing recruitment of endothelial progenitor cells: a new modality to increase efficacy of cell therapy in chronic hind limb ischemia. Circulation. 2006 Dec;114(25): 2823-30.

(35.) Seidl M, Steinbach P, Wörle K, Hofstädter F. Induction of stress fibres and intercellular gaps in human vascular endothelium by shock-waves. Ultrasonics. 1994 Sep; 32(5):397-400.

(36.) Lei H, Liu J, Li H, Wang L, Xu Y, Tian W, et al. Low-intensity shock wave therapy and its application to erectile dysfunction. World J Mens Health. 2013 Dec;31(3):208-14.

(37.) Hausner T, Pajer K, Halat G, Hopf R, Schmidhammer R, Redl H, et al. Improved rate of peripheral nerve regeneration induced by extracorporeal shock wave treatment in the rat. Exp Neurol. 2012 Aug;236(2):363-70.

(38.) Clark DL, Connors BA, Handa RK, Evan AP. Pretreatment with low-energy shock waves reduces the renal oxidative stress and inflammation caused by high-energy shock wave lithotripsy. Urol Res. 2011 Dec;39(6):437-42.

(39.) Sansone V, D’ Agostino MC, Bonora C, Sizzano F, De Girolamo L, Romeo P. Early angiogenic response to shock waves in a three-dimensional model of human microvascular endothelial cell culture (HMEC-1). J Biol Regul Homeost Agents. 2012 Jan-Mar;26(1):29-37.

(40.) Zimpfer D, Aharinejad S, Holfeld J, Thomas A, Dumfarth J, Rosenhek R, et al. Direct epicardial shock wave therapy improves ventricular function and induces angiogenesis in ischemic heart failure. J Thorac Cardiovasc Surg. 2009 Apr;137(4):963-70.

(41.) Fu M, Sun CK, Lin YC, Wang CJ, Wu CJ, Ko SF, et al. Extracorporeal shock wave therapy reverses ischemia-related left ventricular dysfunction and remodeling: molecular-cellular and functional assessment. PLoS One. 2011;6(9):e24342.

(42.) Mittermayr R, Hartinger J, Antonic V, Meinl A, Pfeifer S, Stojadinovic A, et al. Extracorporeal shock wave therapy (ESWT) minimizes ischemic tissue necrosis irrespective of application time and promotes tissue revascularization by stimulating angiogenesis. Ann Surg. 2011 May; 253(5):1024-32.

(43.) Chen YJ, Wurtz T, Wang CJ, Kuo YR, Yang KD, Huang HC, et al. Recruitment of mesenchymal stem cells and expression of TGF-beta 1 and VEGF in the early stage of shock wave-promoted bone regeneration of segmental defect in rats. J Orthop Res. 2004 May;22(3):526-34.

(44.) Nishida T, Shimokawa H, Oi K, Tatewaki H, Uwato-ku T, Abe K, et al. Extracorporeal cardiac shock wave therapy markedly ameliorates ischemia-induced myocardial dysfunction in pigs in vivo. Circulation. 2004 Nov;110(19):3055-61.

(45.) Wang CJ, Wang FS, Yang KD, Weng LH, Hsu CC, Huang CS, et al. Shock wave therapy induces neovascularization at the tendon-bone junction. A study in rab-bits. J Orthop Res. 2003 Nov;21(6):984-9.

(46.) Vardi Y, Appel B, Jacob G, Massarwi O, Gruenwald I. Can low-intensity extracorporeal shock wave therapy improve erectile function? A 6-month follow-up pilot study in patients with organic erectile dysfunction. Eur Urol. 2010 Aug;58(2):243-8.

(47.) Gruenwald I, Appel B, Kitrey ND, Vardi Y. Shockwa-ve treatment of erectile dysfunction. Ther Adv Urol. 2013 Apr;5(2):95-9.

(48.) Lin H, Yuan J, Ruan KH, Yang W, Zhang J, Dai Y, et al. COX-2-10aa-PGIS gene therapy improves erectile function in rats after cavernous nerve injury. J Sex Med. 2013 Jun;10(6):1476-87.

(49.) Lin CS, Xin ZC, Wang Z, Deng C, Huang YC, Lin G, et al. Stem cell therapy for erectile dysfunction: a criti-cal review. Stem Cells Dev. 2012 Feb;21(3):343-51.

(50.) Hatzimouratidis K. Can we cure erectile dysfunction? Eur Urol. 2010 Aug;58(2):249-50.